BLSM Stock Summary and Trading Ideas (Blossomhill Therapeutics | NASDAQ:BLSM)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Blossomhill Therapeutics trades on the NASDAQ stock market under the symbol BLSM.

As of November 12, 2026, BLSM stock price declined to $14.84 with 249,296 million shares trading.

BLSM has a beta of 0.54, meaning it tends to be less sensitive to market movements. BLSM has a correlation of 0.00 to the broad based SPY ETF.

BLSM has a market cap of $471.69 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that BLSM belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.

BLSM support price is $14.72 and resistance is $17.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLSM shares will trade within this expected range on the day.